Biogen Idec, Inc. (NASDAQ:BIIB)
CAPS Rating:
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
RSS Headlines
Fool UK
Recs
There are currently 270 BIIB shares in my "fund" with break-even of around 71.89 USD. http://caps.fool.com/Blogs/fund-trades/678775.